SAHA Unit size Cat. code Docs Qty Price
Pan-Histone deacetylase Inhibitor
25 mg

Pan-Histone deacetylase Inhibitor

SAHA, suberoylanilide hydroxamine, also known as Vorinostat, is a pan-Histone deacetylase inhibitor.

SAHA binds to the active site of histone deacetylases and act as a chelator for Zinc ions also found in the active site of histone deacetylases. SAHA has been in clinical development as a anti-cancer drug, and has antifibrotic and anti-inflammatory potential [1,2].

The antitumor activity of SAHA has been demonstrated both in vitro and in vivo with little or no toxicity to normal cells. Under its trade name Vorinostat, SAHA has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced cutaneous T-cell-lymphoma [3].

Since Histone deacetylases epigenetically silence the transcription of Atg and LC3 genes. Thus, Histone deacetylase inhibitors, as SAHA and Trichostatin A  can lead to an increase of Atg and LC3 proteins levels and promote autophagy.



1. Bolden JE. et al., 2006. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784.
2. Wang Z. et al., 2009. Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? EurRespir J. 34(1):145-155.
3. Mann BS. et al., 2006. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist 12: 1247–1252.

Back to the top


Synonym: Vorinostat.

CAS number: 149647-78-9.

Formula: C14H20N2O3.

Molecular weight: 264.32.

Solubility: 66 mg/ml in DMSO.

Purity: >97% (UHPLC).

Working concentration: 0.1 - 10 µM.

Back to the top


SAHA is provided as a solid:

  • 25 mg SAHA

SAHA is shipped at room temperature.

Upon receipt it should be stored at -20°C.

Solid product is stable 2 years when properly stored.

Back to the top
Customer Service
& Technical Support
Shopping cart is empty